BioSpace News Archive

Cimeio Therapeutics is presenting data for its CD52 program during this week’s Annual Meeting of the American Society of Cell & Gene Therapy (ASGCT) in Baltimore.

ProPhase Labs, Inc., a next-generation biotech, genomics, and diagnostics company, reported its financial and operational results for the three months ended March 31, 2024.

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, reported business updates and financial results for the first quarter of 2024.

Collegium Pharmaceutical, Inc. reported its financial results for the quarter ended March 31, 2024, and provided a corporate update.

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli royalties.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported first quarter 2024 financial results.

Matinas BioPharma Holdings, Inc. reports financial results for the three months ending March 31, 2024 and provides a business update.

The U.S. Food and Drug Administration issued final guidance to provide the medical device industry clarity on the definition of “remanufacturing” for reusable devices needing maintenance or repair.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Jaguar family companies Napo Pharmaceuticals (“Napo”) and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar’s novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.